RECOVER is a clinical study for people who are about to start their first treatment for breast cancer.
All participants in RECOVER will receive chemotherapy treatment with docetaxel and cyclophosphamide (also called TC chemotherapy). Treatment with TC chemotherapy may weaken your body’s ability to fight infections by reducing the number of white blood cells in your body. Because of this, all patients in RECOVER will also receive a medication (either pegfilgrastim or eflapegrastim) that may increase the number of white blood cells in the body.
The purpose of this study is to compare eflapegrastim and pegfilgrastim (also known as Neulasta®*) while you receive TC chemotherapy for early-stage breast cancer, by collecting blood samples and will be looking at the number of white blood cells, including neutrophils, being produced by the body.
You may be able to participate if you:
You should discuss with your doctor whether you might be eligible to participate in RECOVER. More details on what to expect if you participate in RECOVER can be found in the informed consent for the study. Your doctor or study nurse can review this information with you.